Acute Myeloid Leukemia and Myelodysplastic Syndromes | Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes – A Review of the 2022 ASCO Annual Meeting and EHA Congress

Featuring perspectives from Dr Richard Stone, including the following topics: Introduction: RATIFY trial in perspective (0:00) Treatment with FLT3 inhibitors (7:00) Anti-CD47 antibody: Magrolimab (23:04) Anti-TIM-3 antibody: Sabatolimab (31:23) CAR T-cell therapy for acute myeloid leukemia (34:53) Targeted therapy with IDH inhibitors (37:31) New myelodysplastic syndromes classification system (41:20) Hypomethylating agents/venetoclax (45:11) CPX-351 (49:14) Other key data sets (50:59) CME information and select publications